Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcitabine

被引：4
|
作者：
Tomova, A.
Brodowicz, T.
Tzekova, V.
Timcheva, C.
Wiltschke, C.
Gerges, D. A.
Pawlega, J.
Spanik, S.
Inbar, M. J.
Zielinski, C. C.
机构：
[1] Plovdiv Canc Ctr, Plovdiv, Bulgaria
[2] Univ Vienna, Dept Med 1, Vienna, Austria
[3] Univ Hosp, Sofia, Bulgaria
[4] SBALO Natl Oncol Ctr, Sofia, Bulgaria
[5] Rizk Hosp, Beirut, Lebanon
[6] Klin Onkol CmuJ, Krakow, Poland
[7] Onkol Ustav Sv Alzbety, Bratislava, Slovakia
[8] Sourasky Med Ctr, Tel Aviv, Israel
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.1106
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1106
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Gemcitabine plus docetaxel versus capecitabine plus docetaxel for patients with anthracycline-pretreated metastatic breast cancer: a review of the results of a European Phase III trial
    Chan, S
    EJC SUPPLEMENTS, 2005, 3 (05): : 17 - 21
  • [42] A phase III trial of Gemcitabine plus Docetaxel (GD) versus Capecitabine plus Docetaxel (CD) for patients (pt) with anthracycline-pretreated metastatic breast cancer
    Chan, S.
    Sharma, R.
    Romieu, G.
    Huober, T.
    Delozier, T.
    Tubiana-Hulin, M.
    Schneeweiss, A.
    Lluch, A.
    Llombart, A.
    du Bois, A.
    Carrasco, E.
    Thareau, A.
    Fumoleau, P.
    EJC SUPPLEMENTS, 2007, 5 (03): : 15 - 16
  • [43] Neoadjuvant Gemcitabine, Docetaxel, and Capecitabine Followed by Gemcitabine and Capecitabine/Radiation Therapy and Surgery in Locally Advanced, Unresectable Pancreatic Adenocarcinoma
    Sherman, William H.
    Chu, Kyung
    Chabot, John
    Allendorf, John
    Schrope, Beth Ann
    Hecht, Elizabeth
    Jin, Brian
    Leung, David
    Remotti, Helen
    Addeo, Gisella
    Postolov, Inna
    Tsai, Wei
    Fine, Robert L.
    CANCER, 2015, 121 (05) : 673 - 680
  • [44] Sequential Chemotherapy with Gemcitabine and Docetaxel: Breaking the Chains of bacillus Calmette-Guerin
    Meeks, Joshua J.
    Sexton, Wade J.
    Clark, Peter E.
    JOURNAL OF UROLOGY, 2022, 208 (03): : 526 - 527
  • [45] A multicenter phase II randomized study of docetaxel (D)/gemcitabine (G) weekly followed by erlotinib (E) after progression versus erlotinib followed by docetaxel/gemcitabine after progression in advanced non-small cell lung cancer
    Le Caer, H.
    Barlesi, F.
    Corre, R.
    Jullian, H.
    Bota, S.
    Falchero, L.
    Vergnenegre, A.
    Dujon, C.
    Delhoume, J. Y.
    Chouaid, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [46] Phase III Study of Gemcitabine Plus Docetaxel Compared With Capecitabine Plus Docetaxel for Anthracycline-Pretreated Patients With Metastatic Breast Cancer
    Chan, Stephen
    Romieu, Gilles
    Huober, Jens
    Delozier, Thierry
    Tubiana-Hulin, Michele
    Schneeweiss, Andreas
    Lluch, Ana
    Llombart, Antonio
    du Bois, Andreas
    Kreienberg, Rolf
    Mayordomo, Jose Ignacio
    Anton, Antonio
    Harrison, Mark
    Jones, Alison
    Carrasco, Eva
    Vaury, A. Thareau
    Frimodt-Moller, Bente
    Fumoleau, Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (11) : 1753 - 1760
  • [47] Docetaxel/gemcitabine/pembrolizumabVarious toxicities: case report
    Reactions Weekly, 2018, 1688 (1) : 92 - 92
  • [48] Examining gemcitabine and docetaxel for recurrent NMIBC.
    Milbar, Niv
    Kates, Max
    Chappidi, Meera
    Schoenberg, Mark
    Bivalacqua, Trinity J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [49] Docetaxel/gemcitabine/paclitaxelLack of efficacy: case report
    Reactions Weekly, 2023, 1946 (1) : 206 - 206
  • [50] Gemcitabine combined with docetaxel in metastatic breast cancer
    Fumoleau, P
    SEMINARS IN ONCOLOGY, 2003, 30 (02) : 15 - 18
12345